A profitable company with shrinking sales. Institutions are adding.
Facts from SEC filings, not a recommendation.
Last 12 months: $337.0M. Over 5 years, sales grew about 14% a year.
Price chart by TradingView.
From annual reports filed with the SEC. Gross margin doesn't apply to banks and insurers, so it isn't scored. Not in this company's SEC data, so not scored: return on equity 15%+, debt under half of equity, share count not growing. A checklist is a starting point for research, not a verdict.
50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.
SEC filings of any kind. 50 means a normal week.
Institutions added 5.3% to their holdings. 44 bought, 33 sold.
| Insider | Trade | Shares | Avg price | Value | Owns after | Date |
|---|---|---|---|---|---|---|
Jeremy PrahmChief Investment Officer | Sell | 6K | $10.74 | $60K | 150K | Oct 19Filing ↗ |
| ||||||
Jeremy PrahmChief Investment Officer | Sell | 6K | $13.20 | $79K | 156K | Oct 5Filing ↗ |
| ||||||
Kristen N SieffertPresident | Sell | 750 | $12.53 | $9K | 124K | Oct 1Filing ↗ |
| ||||||
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
5,610 shares at $10.74 · $60K
6,000 shares at $13.20 · $79K
750 shares at $12.53 · $9K
6,000 shares at $13.98 · $84K
6,000 shares at $16.82 · $101K
750 shares at $17.55 · $13K
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page